End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
32.23 CNY | -1.20% |
|
-4.98% | +11.18% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 10.16 for the current year.
- The company shows low valuation levels, with an enterprise value at 0.22 times its sales.
- The company appears to be poorly valued given its net asset value.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.18% | 2.29B | D+ | ||
+26.15% | 75.76B | C+ | ||
-2.46% | 23.95B | C+ | ||
+14.23% | 8.7B | B | ||
+1.47% | 8.29B | C | ||
-32.92% | 6.7B | B- | ||
+18.62% | 5.38B | B- | ||
+1.10% | 4.08B | B | ||
-9.24% | 3.79B | B- | ||
-10.20% | 3.3B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000028 Stock
- Ratings China National Accord Medicines Corporation Ltd.